UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026 (Report
No. 3)
Commission File Number: 001-40065
IM Cannabis Corp.
(Exact Name of Registrant as Specified in Charter)
Kibbutz Glil Yam, Central District, Israel 4690500
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form
40-F ☐
CONTENTS
On September 23, 2026, IM Cannabis Corp. (the “Company”)
issued a press release titled: “IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement”. A copy of this
press release is furnished herewith as Exhibit 99.1
This Report of Foreign Private Issuer on Form
6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-296637, 333-293236, 333-289571 and 333-288346 )
filed with the SEC to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
| 99.1 |
Press Release dated September 23, 2026, titled “IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement”. |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
IM CANNABIS CORP. |
| |
(Registrant) |
| |
|
|
| Date: September 23, 2026 |
By: |
/s/ Oren Shuster |
| |
Name: |
Oren Shuster |
| |
Title: |
Chief Executive Officer and Director |
Exhibit 99.1
IM Cannabis Regains
Compliance with Nasdaq Minimum Bid Price Requirement
VANCOUVER and GLIL YAM, Israel, September 23,
2026 - IM Cannabis Corp. (“IMC” or the “Company”) (Nasdaq: IMCC), a medical cannabis company
with operations in Israel and Germany, today announced that on September 23, 2026, it received written notice from Nasdaq Stock Market
LLC (“Nasdaq”), indicating that the Company has regained compliance with the minimum bid price requirement set forth
in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
The Nasdaq staff made this determination of compliance
after the closing bid price of the Company’s ordinary shares was $1.00 per share or greater for the 18 consecutive business days
from August 27 to September 22, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq
considers the bid price deficiency matter now closed.
About IM Cannabis Corp.
IMCC (Nasdaq: IMCC) is an international company
currently operating a medical cannabis platform serving patients in Israel and, through Adjupharm GmbH, Germany. Following completion
of the pending transactions announced by the Company on August 17, 2026, the Company expects to retain its Israeli medical cannabis operations
and the German operations will be sold.
The IMCC ecosystem operates in Israel through
its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights.
The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality
control of IMCC’s products throughout the value chain.
Company Contact:
Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com
